WHITEHOUSE STATION, N.J. – Merck & Co. says the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old.
Meant as an alternative to weekly allergy shots, the tablet dissolves under the tongue. Taken daily for a few years, it gradually reduces sensitivity to common grasses, instead of temporarily relieving symptoms including sneezing, runny nose, and itchy, watery eyes.
Get weekly health news
Merck, based in Whitehouse Station, N.J., will market the tablet in North America. Its partner, ALK-Abello, sells it in Europe as Grazas.
- Late spring start, dry conditions to blame for intense Edmonton allergy season
- Woman with terminal cancer climbs Mt. Everest to show possibilities are limitless
- N.B. should halt transition to new virtual-health-care provider: Opposition Tories
- Ebola outbreak is ‘very complex,’ but ‘can be stopped’, WHO chief says
Merck said Grastek will be available in U.S. pharmacies in late April. However, it’s best to start taking it three months before grass pollen season begins.
The drug can cause severe allergic reactions and shouldn’t be used by patients with severe asthma.
Comments
Want to discuss? Please read our Commenting Policy first.